A founding executive of Dracen, Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immuno-oncology deals. Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Roche (member of the Roche Group) and prior to that global commercial leader for oncology at Pfizer. He also held various positions at Ortho Biotech and Schering-Plough (now Merck & Co.). He holds a Master Degree in Radiation Oncology from Cairo University School of Medicine and a Bachelor of Medicine and Surgery degree from Cairo University School of Medicine.

Mr. Estok brings 30+ years of experience in development and commercialization of pharmaceuticals to Dracen.  Previously, he was the founding President/CEO of Tragara Pharmaceuticals, founding President/CEO of Cabrellis Pharmaceuticals where he led the organization’s development of amrubicin prior to its acquisition by Pharmion, and served as Chief Commercial Officer of Conforma Therapeutics whose HSP90 franchise was acquired by Biogen-Idec. A 19-year veteran of Schering-Plough, Mr. Estok held a number of positions with progressing responsibility in R&D (biochemistry and oncology operations management), in both US and global marketing, European operations, sales and commercial development. His most recent position was Vice President, US Marketing and Commercial Development, Oncology. Mr. Estok has led multidisciplinary R&D, business development, and commercial teams and is a recognized leader in the commercialization of oncology therapeutics and the formation/growth of new divisions and companies. Mr. Estok graduated from Virginia Tech with a BS degree in Biochemistry and was awarded an MBA from Fairleigh Dickinson University. He is currently a Board Director at Adastra Pharmaceuticals.